Showing 1481-1490 of 2216 results for "".
- BTL Introduces Emsella Applicator for Emsculpt Platformhttps://modernaesthetics.com/news/btl-introduces-emsella-applicator-for-emsculpt-platform/2472892/BTL is launching the new Emsella applicator with up to 2.5 Tesla (T) to treat all forms of male and female urinary incontinence. Building upon the existing clearances for Emsculpt for the abdomen, buttocks, thighs, arms and calves, the new Emsella applicator makes Emsculpt the first system to tre
- Aaron Burton Named CEO at Scitonhttps://modernaesthetics.com/news/aaron-burton-named-ceo-at-sciton/2472888/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently o
- BTL Suit Alleges False Advertising by Allerganhttps://modernaesthetics.com/news/btl-suit-alleges-false-advertising-by-allergan-1/2472885/In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges that Allergan's marketing, sales materials, and soci
- Allergan's New Philanthropic Program Will Benefit Kids with Upper Limb Spasticityhttps://modernaesthetics.com/news/allergans-new-philanthropic-program-will-benefit-kids-with-upper-limb-spasticity/2472879/Allergan is launching the Be The Difference philanthropic program to support children and their families who may benefit from treatment with Botox (onabotulinumtoxinA) for pediatric upper limb spasticity. Botox is approved to treat increased muscle stiffness in children 2 to 17 years of
- Revian: USPTO Grants Patent for Biostimulatory Approachhttps://modernaesthetics.com/news/regina-uspto-grants-patent-for-biostimulatory-approach/2472862/The United States Patent and Trademark Office (USPTO) has awarded to Revian Inc. U.S. Patent No. 10,265,258—the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body. The claims in this issued patent cover the use
- Amorepacific Debuts Face Mask 3D Printing System and Flexible LED Beauty Device at CES 2020https://modernaesthetics.com/news/amorepacific-debuts-face-mask-3d-printing-system-and-flexible-led-beauty-device-at-ces-2020/2472861/Amorepacific is presenting its 3D face mask printing system (IOPE Tailored 3D Mask) and flexible LED beauty device (MakeON Flexible LED Patch) at the Consumer Electronics Show 2020 (CES 2020) in Las Vegas. Created in collaboration with the 3D printing system developer Lincsolu
- BTL Files Patent Infringement Lawsuit Against Allergan and Zimmer Related to Emsculpthttps://modernaesthetics.com/news/btl-files-patent-infringement-lawsuit-against-allergan-and-zimmer-related-to-emsculpt/2472855/BTL Aesthetics' US affiliate has filed a lawsuit against Allergan plc, Ireland and its affiliates, and Zimmer MedizinSysteme GmbH, Germany, and its affiliate, in the US Federal District Court for the District of Delaware. The lawsuit asserts
- Ortho Dermatologics Adds Key Staff to Solta Medical Business Unithttps://modernaesthetics.com/news/ortho-dermatologics-adds-key-staff-to-solta-medical-business-unit/2472854/Ortho Dermatologics is staffing up its Solta Medical Business unit. The new appointments include the following: Liz Newman, General Manager, Solta, North America Newman first joined Solta
- ISAPS: Brazil, US Remain Cosmetic Surgery Capitals of the Worldhttps://modernaesthetics.com/news/isaps-brazil-us-remain-cosmetic-surgery-capitals-of-the-world/2472850/Driven by increases in non-invasive procedures, plastic surgery across the globe is on the rise, according to the annual statistics from the International Society of Aesthetic Plastic Surgery (ISAPS), and the US and Brazil remain the cosmetic surgery capitals o
- It's A Deal: Baring Private Equity Asia Agrees to Acquire Lumenishttps://modernaesthetics.com/news/its-a-deal-baring-private-equity-asia-agrees-to-acquire-lumenis/2472848/Baring Private Equity Asia’s affiliated private equity funds are acquiring Lumenis. The transaction, which values Lumenis at an enterprise value of more than $1 billion, remains subject to the customary regulatory approval process. It is expected to be completed in early 2020. <